In 2023, Germany led global antihypertensive medicine sales with $418.5 million, despite a slight year-on-year decline of -0.53%. Croatia and Finland showed significant growth rates of 8.27% and 7.73% respectively. Notably, Luxembourg experienced the highest increase with a 9.86% rise. In contrast, Czech Republic faced the steepest decline at -5.45%. Over the last five years, these variations indicate a compound annual growth rate (CAGR) that underscores dynamic shifts in the market landscape.
Emerging trends to watch include increased sales in developing nations as access to healthcare improves, advancements in medication that may change market dynamics, and potential impacts from global health policies and economic conditions. Monitoring these factors will be crucial for understanding future market directions.
Top countries in Antihypertensive Medicine Sales by Country
# | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
---|---|---|---|---|---|---|
1 | 1 Germany | 418.5 | 2023 | +1.09% | -0.53% | View data |
2 | 2 Croatia | 179.4 | 2023 | +3.7% | +8.27% | View data |
3 | 3 Canada | 103.5 | 2023 | +14.62% | +3.11% | View data |
4 | 4 Czech Republic | 44.8 | 2023 | -4.27% | -5.45% | View data |
5 | 5 Slovakia | 34.1 | 2023 | +1.79% | -0.91% | View data |
6 | 6 Chile | 16.6 | 2023 | +3.75% | -1.16% | View data |
7 | 7 Finland | 11.9 | 2023 | +3.48% | +7.73% | View data |
8 | 8 Slovenia | 9 | 2023 | +1.12% | +7.74% | View data |
9 | 9 Estonia | 2.4 | 2023 | +4.35% | +4.78% | View data |
10 | 10 Luxembourg | 0.8 | 2023 | 0% | +9.86% | View data |